Adaptive Biotechnologies Corp reports results for the quarter ended December 31 - Earnings Summary

• Adaptive Biotechnologies Corp ADPT.OQ reported a quarterly adjusted loss of 23 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -30 cents. The mean expectation of eight analysts for the quarter was for a loss of 26 cents per share. Wall Street expected results to range from -32 cents to -21 cents per share.

• Revenue rose 3.7% to $47.46 million from a year ago; analysts expected $46.03 million.

• Adaptive Biotechnologies Corp's reported EPS for the quarter was a loss of 23 cents​.

• The company reported a quarterly loss of $33.69 million.

• Adaptive Biotechnologies Corp shares had risen by 28.1% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Adaptive Biotechnologies Corp is $7.50

This summary was machine generated from LSEG data February 11 at 10:42 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)